疫苗技術及全球市場 是由出版商BCC Research在2011年01月所出版的。
這份英文市場調查報告書包含199 Pages 價格從美金4850起跳。
全球疫苗市場於2009年止預計達到252億美金，今後將以CAGR17.9%持續增加，2015年止達到642億美金規模。
本報告為，匯整全球疫苗市場趨勢及法規、疫苗可預防之疾病概要、今後展望、市場參與企業簡介等，以下列摘要形式闡述。
第1章 簡介
第2章 實施概要
第3章 概要
- 何謂疫苗
- 疫苗歷史
- 弱毒疫苗
- 惰性化疫苗
- 類毒素疫苗
- DNA疫苗，其他
第4章 患病率
第5章 法規概要
第6章 產業結構
- WHO已經許可之疫苗製造商／供應商
- 人體疫苗製造商／供應商，其他
第7章 新發展
第8章 市場分析：人體
- 弱毒疫苗
- 惰性化疫苗
- 共軛疫苗
- DNA重組疫苗
- 亞單位疫苗
- 類毒素疫苗
- 聯合疫苗
第9章 動物醫療市場
第10章 應用別市場：人體
第11章 專利分析
第12章 全球疫苗市場現況
- 全球疫苗市場
- 影響疫苗銷售因素
- 競合
- 成本
- 趨勢
- 疫苗接種預算
- 現況
- 疫苗可預防之疾病
第13章 企業簡介
Abstract
Highlights
- Global sales of human and animal vaccines reached approximately $25.2
billion in 2009. The market is expected to rise at a compound annual growth
rate (CAGR) of 17.9% to reach $64.2 billion by 2015.
- The global market for human vaccines in 2008 was $18.7 billion and, with a
continuing increase in the global market, reached $21.2 billion in 2009. This
market is expected to rise at a compound annual growth rate (CAGR) of 19.6% to
reach $58.6 billion by the end of 2015.
The animal vaccines market grew from approximately $3.8 billion in 2008 to
about $4.0 billion in 2009, an increase of about 5.9%. This market is expected
to increase at a 5.7% compound annual growth rate (CAGR) between 2010 and 2015
to reach $5.6 billion in 2015.
INTRODUCTION
STUDY OBJECTIVES
BCC' s goal in conducting this study is to provide an overview of the current
and future characteristics of the global market for human and animal
(veterinary) vaccines and related vaccine technologies. The key objective is
to present a comprehensive analysis of the current market and its future
direction in the human and animal (veterinary) vaccines market with their
utilization and employment in preventing and/or treating infectious diseases.
This report explores present and future strategies within the human and animal
(veterinary) vaccines market, including attenuated (live) vaccines,
inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA
(rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines.
The current state of the market, the setbacks, the innovations, and the future
needs of the market are discussed in this report. A general overview of
vaccines, and related technologies used currently and in the past are
discussed in the report.
A detailed analysis of the vaccine industry structure has been conducted. This
includes all seven major categories of vaccines broken down by market share
belonging to leading manufacturers and/or suppliers. Revenues for each of the
seven categories of vaccines are broken down by region. Sales figures are
estimated for the 5 - year period from 2010 through 2015.
Applications for human and animal (veterinary) vaccines, as to their
prophylactic or therapeutic use are also discussed separately in the report,
with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines,
pediatric vaccines, adult/adolescent vaccines, travel vaccines, and others.
The report also includes significant patents and their allotments in each
vaccine technology category.
REASONS FOR DOING THIS STUDY
This study was conducted to provide vital and detailed information regarding
human and animal (veterinary) vaccines. The vaccines industry is experiencing
growth due to new products hitting the market as well as a general increase in
public awareness and more standardized immunization schedules. This study was
conducted to provide detailed market analysis of human and animal (veterinary)
vaccines along with the different factors affecting this market. While the
vaccines market was affected by the global economic downturn, it retained
steady growth and new developments are expected to further influence the
market.
Acquisitions, mergers, and alliances by companies and global organizations are
covered in this report. The study also discusses the strengths and weaknesses
of each category of vaccines in addition to any new technologies/developments,
manufacturer/supplier competition, as well as changing immunization coverage
rates.
INTENDED AUDIENCE
This study contributes to the areas of market growth in preventing some
disease types through vaccination from the point of view of manufacturers and
users. Clinicians, physicians, the pharmaceutical and biopharmaceutical
industries, hospitals and research institutes will find this study to be of
interest.
SCOPE OF THE STUDY
The scope of this study encompasses the vaccine human and animal (veterinary)
markets. BCC analyzes each market and its applications by its need for disease
type requiring vaccination, regulatory environment, technology involved,
market projections, and market share. Technological issues include the latest
trends and developments.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
study. BCC conducted a comprehensive literature search, which included
technical newsletters and journals, and many other sources. Data were
collected through interviews and correspondence with various
analytical/chemical/pharmaceutical/biotechnical experts. Projections were
based on estimates such as the current number of end users, potential end
users, mergers and acquisitions, and market trends.
INFORMATION SOURCES
Many companies within the industry were surveyed to obtain data for this
study. Included were manufacturers and end users of pharmaceuticals. Data were
gathered from various industry sources. BCC spoke with officials and
physicians within the industry, consulted newsletters, company literature,
product literature, and a host of technical articles, journals, indexes, and
abstracts. Exhaustive investigations of databases by key terminology were
completed. In addition, data were compiled from current financial, trade, and
government sources.
Table of Contents
Chapter- 1: INTRODUCTION -- Complimentary
- STUDY OBJECTIVES
- REASONS FOR DOING THIS STUDY
- INTENDED AUDIENCE
- SCOPE OF THE STUDY
- METHODOLOGY
- INFORMATION SOURCES
- ABOUT THE AUTHOR
- RELATED BCC RESEARCH REPORTS
- BCC ONLINE SERVICES
- DISCLAIMER
Chapter-2: EXECUTIVE SUMMARY
- EXECUTIVE SUMMARY
- SUMMARY TABLE GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, THROUGH 2015 ($
MILLIONS)
- SUMMARY FIGURE GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, 2008-2015 ($
MILLIONS)
Chapter-3: OVERVIEW
- WHAT IS A VACCINE?
- HISTORY OF VACCINES
- TABLE 1 HISTORY OF VACCINES, 1996-2006
- TABLE 1 (CONTINUED)
- TYPES OF VACCINES
- ATTENUATED (LIVE) VACCINES
- Applications of Attenuated (Live) Vaccines
- TABLE 2 APPLICATIONS OF ATTENUATED (LIVE) VACCINES
- Advantages and Disadvantages of Attenuated (Live) Vaccines
- TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES
- TABLE 3 (CONTINUED)
- INACTIVATED (KILLED) VACCINES
- Applications of Inactivated (Killed) Vaccines
- TABLE 4 APPLICATIONS OF INACTIVATED (KILLED) VACCINES
- TABLE 4 (CONTINUED)
- Advantages and Disadvantages of Inactivated (Killed) Vaccines
- TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVED (KILLED) VACCINES
- TOXOID VACCINES
- Applications of Toxoid Vaccines
- TABLE 6 APPLICATIONS OF TOXOID VACCINES
- Advantages and Disadvantages of Toxoid Vaccines
- TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES
- SUBUNIT VACCINES
- Applications of Subunit Vaccines
- TABLE 8 APPLICATIONS OF SUBUNIT VACCINES
- Advantages and Disadvantages of Subunit Vaccines
- TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES
- CONJUGATE VACCINES
- Applications of Conjugate Vaccines
- TABLE 10 APPLICATIONS OF CONJUGATE VACCINES
- Advantages and Disadvantages of Conjugate Vaccines
- TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES
- RECOMBINANT VECTOR VACCINES
- Applications of Recombinant Vector Vaccines
- TABLE 12 APPLICATIONS OF RECOMBINANT VECTOR VACCINES
- Advantages and Disadvantages of Recombinant Vector Vaccines
- TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR VACCINES
- DNA VACCINES
- Applications of DNA Vaccines
- TABLE 14 APPLICATIONS OF DNA VACCINES
- Advantages and Disadvantages of DNA Vaccines
- TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES
- INFECTIOUS DISEASES PREVENTABLE BY VACCINES
- HUMAN DISEASES
- Viral Diseases
- TABLE 16 VACCINE - PREVENTABLE HUMAN VIRAL DISEASES
- TABLE 16 (CONTINUED)
- TABLE 16 (CONTINUED)
- Bacterial Diseases
- TABLE 17 VACCINE - PREVENTABLE HUMAN BACTERIAL DISEASES
- TABLE 17 (CONTINUED)
- TABLE 17 (CONTINUED)
- ANIMAL DISEASES
- TABLE 18 VACCINE - PREVENTABLE ANIMAL DISEASES IN COMPANION ANIMALS
- TABLE 18 (CONTINUED)
- TABLE 19 VACCINE - PREVENTABLE ANIMAL DISEASES IN LIVESTOCK ANIMALS
- TABLE 19 (CONTINUED)
- TABLE 20 LIVESTOCK ANIMAL VACCINES
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
Chapter-4: PREVALENCE
- INCIDENCE AND IMMUNIZATION OF HUMAN DISEASES
- REGIONAL DATA
- TABLE 21 REPORTED INCIDENCE DATA OF HUMAN DISEASES, BY REGION, 2007-2009
- TABLE 21 (CONTINUED)
- TABLE 22 IMMUNIZATION COVERAGE DATA OF HUMAN DISEASES, BY REGION,
2007-2009 (%)
- TABLE 22 (CONTINUED)
- GLOBAL DATA
- TABLE 23 REPORTED CASES OF HUMAN DISEASES, 2007 AND 2008
- TABLE 24 IMMUNIZATION COVERAGE OF HUMAN DISEASES (%)
- GLOBAL IMMUNIZATION UPTAKE DATA
- TABLE 25 UPTAKE OF NEW AND UNDERUSED VACCINES, 2008
- GLOBAL DEATHS DUE TO VACCINE - PREVENTABLE DISEASES
- TABLE 26 GLOBAL CHILD DEATHS DUE TO VACCINE - PREVENTABLE DISEASES, 2008
Chapter-5: REGULATORY ASPECTS
- TABLE 27 REVISIONS TO EXISTING VACCINES, 2007-2010
- TABLE 27 (CONTINUED)
- TABLE 27 (CONTINUED)
- TABLE 27 (CONTINUED)
- TABLE 27 (CONTINUED)
- TABLE 27 (CONTINUED)
- TABLE 28 NEW VACCINES IN THE GLOBAL MARKET, 2007-2010
- TABLE 28 (CONTINUED)
- TABLE 28 (CONTINUED)
- TABLE 28 (CONTINUED)
- TABLE 28 (CONTINUED)
Chapter-6: INDUSTRY STRUCTURE
- WHO - PREQUALIFIED VACCINE MANUFACTURERS/SUPPLIERS
- TABLE 29 WORLD HEALTH ORGANIZATION (WHO) - PREQUALIFIED
MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES, 2010
- TABLE 29 (CONTINUED)
- MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES
- ATTENUATED (LIVE) VACCINES
- TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES
- TABLE 30 (CONTINUED)
- INACTIVATED (KILLED) VACCINES
- TABLE 31 LEADING MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES
- CONJUGATE VACCINES
- TABLE 32 LEADING MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES
- RECOMBINANT / RECOMBINANT DNA (RDNA) VACCINES
- TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT/ RECOMBINANT DNA
(RDNA) VACCINES
- TABLE 33 (CONTINUED)
- SUBUNIT VACCINES
- TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF SUBUNIT VACCINES
- TOXOID VACCINES
- TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF TOXOID VACCINES
- COMBINATION VACCINES
- TABLE 36 LEADING MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES
- MARKET SHARES OF INDUSTRY LEADERS OF HUMAN VACCINES
- ATTENUATED (LIVE) VACCINES
- TABLE 37 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED
(LIVE) VACCINES, 2009 (%)
- FIGURE 1 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED
(LIVE) VACCINES, 2009 (%)
- INACTIVATED (KILLED) VACCINES
- TABLE 38 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED
(KILLED) VACCINES, 2009 (%)
- FIGURE 2 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED
(KILLED) VACCINES, 2009 (%)
- CONJUGATE VACCINES
- TABLE 39 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE
VACCINES, 2009 (%)
- FIGURE 3 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE
VACCINES, 2009 (%)
- RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES
- TABLE 40 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF
RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009 (%)
- FIGURE 4 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF
RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009 (%)
- SUBUNIT VACCINES
- TABLE 41 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUBUNIT
VACCINES, 2009 (%)
- FIGURE 5 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF SUBUNIT
VACCINES, 2009 (%)
- TOXOID VACCINES
- TABLE 42 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF TOXOID
VACCINES, 2009 (%)
- FIGURE 6 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF TOXOID
VACCINES, 2009 (%)
- COMBINATION VACCINES
- TABLE 43 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION
VACCINES, 2009 (%)
- FIGURE 7 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION
VACCINES, 2009 (%)
Chapter-7: NEW DEVELOPMENTS
Chapter SEVEN: NEW DEVELOPMENTS
- NEW DEVELOPMENTS
- TABLE 44 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF HUMAN VACCINES (AS
OF AUGUST 2010)
- TABLE 44 (CONTINUED)
- TABLE 44 (CONTINUED)
- TABLE 44 (CONTINUED)
- TABLE 44 (CONTINUED)
- TABLE 44 (CONTINUED)
Chapter-8: MARKET ANALYSIS: HUMAN
- TABLE 45 GLOBAL MARKET FOR HUMAN VACCINES BY REGION, THROUGH 2015 ($
MILLIONS)
- FIGURE 8 GLOBAL MARKET FOR HUMAN VACCINES BY REGION, 2008-2015 ($ MILLIONS)
- ATTENUATED (LIVE) VACCINES
- MARKET OVERVIEW
- MARKET REVENUE
- TABLE 46 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES, BY REGION,
THROUGH 2015 ($ MILLIONS)
- FIGURE 9 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES, BY REGION,
2008-2015 ($ MILLIONS)
- INACTIVATED (KILLED) VACCINES
- MARKET OVERVIEW
- MARKET REVENUE
- TABLE 47 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, THROUGH 2015 ($
MILLIONS)
- FIGURE 10 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, 2008-2015 ($
MILLIONS)
- CONJUGATE VACCINES
- MARKET OVERVIEW
- MARKET REVENUE
- TABLE 48 GLOBAL MARKET FOR CONJUGATE VACCINES, THROUGH 2015 ($ MILLIONS)
- FIGURE 11 GLOBAL MARKET FOR CONJUGATE VACCINES, 2008-2015 ($ MILLIONS)
- RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES
- MARKET OVERVIEW
- MARKET REVENUE
- TABLE 49 GLOBAL MARKET FOR RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES,
THROUGH 2015 ($ MILLIONS)
- FIGURE 12 GLOBAL MARKET FOR RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES,
2008-2015 ($ MILLIONS)
- SUBUNIT VACCINES
- MARKET OVERVIEW
- MARKET REVENUE
- TABLE 50 GLOBAL MARKET FOR SUBUNIT VACCINES, THROUGH 2015 ($ MILLIONS)
- FIGURE 13 GLOBAL MARKET FOR SUBUNIT VACCINES, 2008-2015 ($ MILLIONS)
- TOXOID VACCINES
- MARKET OVERVIEW
- MARKET REVENUE
- TABLE 51 GLOBAL MARKET FOR TOXOID VACCINES, THROUGH 2015 ($ MILLIONS)
- FIGURE 14 GLOBAL MARKET FOR TOXOID VACCINES, 2008-2015 ($ MILLIONS)
- COMBINATION VACCINES
- MARKET OVERVIEW
- MARKET REVENUE
- TABLE 52 GLOBAL MARKET FOR COMBINATION VACCINES, BY REGION THROUGH 2015 ($
MILLIONS)
- FIGURE 15 GLOBAL MARKET FOR COMBINATION VACCINES, BY REGION, 2008-2015 ($
MILLIONS)
- MARKET SHARES OF HUMAN VACCINES, BY REGION
- TABLE 53 GLOBAL HUMAN VACCINES MARKET SHARES BY REGION, 2009 (%)
- FIGURE 16 GLOBAL HUMAN VACCINES MARKET SHARES BY REGION, 2009 (%)
- MARKET SHARES OF HUMAN VACCINES, BY TYPE
- TABLE 54 GLOBAL HUMAN VACCINES MARKET SHARES BY VACCINE TYPE, 2009 (%)
- FIGURE 17 GLOBAL HUMAN VACCINES MARKET SHARES BY VACCINE TYPE, 2009 (%)
Chapter-9: ANIMAL HEALTH MARKET
- INDUSTRY MANUFACTURERS OF ANIMAL HEALTH PRODUCTS
- MARKET OVERVIEW
- MARKET REVENUE
- TABLE 55 GLOBAL ANIMAL HEALTH REVENUES BY MARKET LEADERS, 2008-2010 ($
MILLIONS)
- TABLE 56 GLOBAL ANIMAL HEALTH MARKET SHARES BY REVENUE, 2009 (%)
- FIGURE 18 GLOBAL ANIMAL HEALTH MARKET SHARES BY REVENUE, 2009 (%)
- ANIMAL VACCINES
- TABLE 57 GLOBAL MARKET FOR ANIMAL VACCINES, THROUGH 2015 ($ MILLIONS)
- FIGURE 19 GLOBAL MARKET FOR ANIMAL VACCINES, 2008-2015 ($ MILLIONS)
Chapter-10: MARKET BY APPLICATIONS - HUMANS
- TABLE 58 DISEASES AND INFECTIONS WITH DEVELOPED HUMAN VACCINES BASED ON
MICROORGANISM
- TABLE 59 DISEASES AND INFECTIONS WITH DEVELOPED HUMAN VACCINES BASED ON
TREATMENT
- MENINGOCOCCAL/PNEUMOCOCCAL DISEASES
- MARKET REVENUE
- TABLE 60 GLOBAL SALES OF HUMAN VACCINES IN MENINGOCOCCAL/ PNEUMOCOCCAL
DISEASES MARKET, THROUGH 2015 ($ MILLIONS)
- FIGURE 20 GLOBAL SALES OF HUMAN VACCINES IN MENINGOCOCCAL/ PNEUMOCOCCAL
DISEASES MARKET, 2008-2015 ($ MILLIONS)
- TABLE 61 TOP - SELLING GROUPS OF MENINGOCOCCAL/ PENUMOCOCCAL VACCINES FOR
2009 BY MARKET SHARE (%)
- INFLUENZA (SEASONAL AND PANDEMIC) DISEASES
- MARKET REVENUE
- TABLE 62 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET,
THROUGH 2015 ($ MILLIONS)
- FIGURE 21 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET,
2008-2015 ($ MILLIONS)
- TABLE 63 TOP - SELLING GROUPS OF INFLUENZA VACCINES BY MARKET SHARE, 2009
(%)
- PEDIATRIC/POLIO/PERTUSSIS/HIB DISEASES
- MARKET REVENUE
- TABLE 64 GLOBAL SALES OF HUMAN VACCINES IN PEDIATRIC/POLIO' PERTUSSIS/HIB
DISEASES MARKET, THROUGH 2015 ($ MILLIONS)
- FIGURE 22 GLOBAL SALES OF HUMAN VACCINES IN PEDIATRIC/ POLIO/PERTUSSIS/HIB
DISEASES MARKET, 2008-2015 ($ MILLIONS)
- TABLE 65 TOP - SELLING GROUPS OF PEDIATRIC/POLIO/PERTUSSIS/HIB VACCINES BY
MARKET SHARE, 2009 (%)
- ADULT/ADOLESCENT BOOSTER RELATED DISEASES
- MARKET REVENUE
- TABLE 66 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER -
RELATED DISEASES MARKET, THROUGH 2015 ($ MILLIONS)
- FIGURE 23 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER -
RELATED DISEASES MARKET, 2008-2015 ($ MILLIONS)
- TABLE 67 TOP - SELLING GROUPS OF ADULT/ADOLESCENT BOOSTER - RELATED
VACCINES BY MARKET SHARE, 2009 (%)
- TRAVEL AND OTHER ENDEMIC DISEASES
- MARKET REVENUE
- TABLE 68 GLOBAL SALES OF HUMAN VACCINES IN TRAVEL AND OTHER ENDEMIC
DISEASES MARKET, THROUGH 2015 ($ MILLIONS)
- FIGURE 24 GLOBAL SALES OF HUMAN VACCINES IN TRAVEL AND OTHER ENDEMIC
DISEASES MARKET, 2008- 2015 ($ MILLIONS)
- TABLE 69 TOP - SELLING GROUPS OF TRAVEL AND OTHER ENDEMIC VACCINES BY
MARKET SHARE, 2009 (%)
- HPV DISEASE
- MARKET REVENUE
- TABLE 70 GLOBAL SALES OF HUMAN VACCINES IN HPV DISEASE MARKET, THROUGH
2015 ($ MILLIONS)
- FIGURE 25 GLOBAL SALES OF HUMAN VACCINES IN HPV DISEASE MARKET, 2008-2015
($ MILLIONS)
- TABLE 71 TOP - SELLING HPV VACCINES IN THE ORDER OF THEIR SALES, 2009 (%)
- ROTAVIRUS DISEASE
- MARKET REVENUE
- TABLE 72 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS DISEASE MARKET,
THROUGH 2015 ($ MILLIONS)
- FIGURE 26 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS DISEASE MARKET,
2008-2015 ($ MILLIONS)
- TABLE 73 TOP - SELLING ROTAVIRUS VACCINES BY MARKET SHARE, 2009 (%)
- OTHER DISEASES
- MARKET REVENUE
- TABLE 74 GLOBAL SALES OF HUMAN VACCINES IN OTHER DISEASES MARKET, THROUGH
2015 ($ MILLIONS)
- FIGURE 27 GLOBAL SALES OF HUMAN VACCINES IN OTHER DISEASES MARKET,
2008-2015 ($ MILLIONS)
- TABLE 75 TOP - SELLING OTHER VACCINES FOR 2009 BY MARKET SHARE (%)
- MARKET SHARE OF APPLICATIONS
- TABLE 76 SHARE OF VARIOUS CATEGORIES OF VACCINES IN THE HUMAN VACCINES
MARKET, 2009 (%)
- FIGURE 28 SHARE OF VARIOUS CATEGORIES OF VACCINES IN THE HUMAN VACCINES
MARKET, 2009 (%)
Chapter-11: PATENT ANALYSIS
- TOTAL NUMBER OF PATENTS
- TABLE 77 NUMBER OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER 2010
- FIGURE 29 NUMBER OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER 2010
- FIGURE 30 PERCENT OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER 2010 (%)
- PATENTS BY TYPE AND YEAR
- TABLE 78 PATENTS BY TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 31 PATENTS BY TECHNOLOGY, 2006 TO SEPTEMBER 2010
- PATENTS BY COMPANY
- INACTIVATED (KILLED) VACCINE TECHNOLOGY
- TABLE 79 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING INACTIVATED (KILLED)
VACCINE TECHNOLOGY, 2006 TO SPETEMBER 2010
- FIGURE 32 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING INACTIVATED (KILLED)
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- ATTENUATED (LIVE) VACCINE TECHNOLOGY
- TABLE 80 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING ATTENUATED (LIVE)
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 33 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING ATTENUATED (LIVE)
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- CONJUGATE VACCINE TECHNOLOGY
- TABLE 81 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING CONJUGATE VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 34 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING CONJUGATE VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- TOXOID VACCINE TECHNOLOGY
- TABLE 82 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING TOXOID VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 35 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING TOXOID VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- RECOMBINANT/RDNA VACCINE TECHNOLOGY
- TABLE 83 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING RECOMBINANT/RDNA
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- TABLE 83 (CONTINUED)
- FIGURE 36 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING RECOMBINANT/RDNA
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- SUBUNIT VACCINE TECHNOLOGY
- TABLE 84 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING SUBUNIT VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 37 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING SUBUNIT VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- OTHER/COMBINED VACCINE TECHNOLOGY
- TABLE 85 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING OTHER/COMBINED
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- TABLE 85 (CONTINUED)
- FIGURE 38 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING OTHER/ COMBINED
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- PATENTS BY COUNTRY
- INACTIVATED (KILLED) VACCINE TECHNOLOGY
- TABLE 86 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING INACTIVATED (KILLED)
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 39 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING INACTIVATED (KILLED)
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- ATTENUATED (LIVE) VACCINE TECHNOLOGY
- TABLE 87 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING ATTENUATED (LIVE)
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- TABLE 87 (CONTINUED)
- FIGURE 40 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING ATTENUATED (LIVE)
VACCINE TECHNOLOGY, 2006 - 2010
- CONJUGATE VACCINE TECHNOLOGY
- TABLE 88 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING CONJUGATE VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 41 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING CONJUGATE VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- TABLE 89 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING TOXOID VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 42 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING TOXOID VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- RECOMBINANT/ DNA/ RDNA VACCINE TECHNOLOGY
- TABLE 90 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING RECOMBINANT/DNA/RDNA
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 43 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING RECOMBINANT/DNA/RDNA
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- SUBUNIT VACCINE TECHNOLOGY
- TABLE 91 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING SUBUNIT VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 44 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING SUBUNIT VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- OTHER/COMBINED VACCINE TECHNOLOGY
- TABLE 92 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING OTHER/COMBINED
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 45 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING OTHER/COMBINED
VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010
- TABLE 93 NUMBER OF U.S. PATENTS BY COUNTRY FOR ALL VACCINE TYPES, 2006 TO
SEPTEMBER 2010 (%)
- TABLE 93 (CONTINUED)
- FIGURE 46 PATENT SHARES BY COUNTRY FOR VACCINES, 2006 TO SEPTEMBER 2010
(%)
- PATENTS BY ASSIGNEE
- INACTIVATED (KILLED) VACCINE TECHNOLOGY
- TABLE 94 PATENTS BY ASSIGNEE UTILIZING INACTIVATED (KILLED) VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 47 PATENTS BY ASSIGNEE UTILIZING INACTIVATED (KILLED) VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- ATTENUATED (LIVE) VACCINE TECHNOLOGY
- TABLE 95 PATENTS BY ASSIGNEE UTILIZING ATTENUATED (LIVE) VACCINE
TECHNOLOGY, 2006 THROUGH SEPTEMBER 2010
- FIGURE 48 PATENTS BY ASSIGNEE UTILIZING ATTENUATED (LIVE) VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- CONJUGATE VACCINE TECHNOLOGY
- TABLE 96 PATENTS BY ASSIGNEE UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006
TO SEPTEMBER 2010
- FIGURE 49 PATENTS BY ASSIGNEE UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006
TO SEPTEMBER 2010
- TOXOID VACCINE TECHNOLOGY
- TABLE 97 PATENTS BY ASSIGNEE UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO
SEPTEMBER 2010
- FIGURE 50 PATENTS BY ASSIGNEE UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO
SEPTEMBER 2010
- RECOMBINANT/RDNA VACCINE TECHNOLOGY
- TABLE 98 PATENTS BY ASSIGNEE UTILIZING RECOMBINANT/RDNA VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- FIGURE 51 PATENTS BY ASSIGNEE UTILIZING RECOMBINANT/RDNA VACCINE
TECHNOLOGY, 2006 TO SEPTEMBER 2010
- SUBUNIT VACCINE TECHNOLOGY
- TABLE 99 PATENTS BY ASSIGNEE UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO
SEPTEMBER 2010
- FIGURE 52 PATENTS BY ASSIGNEE UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006
TO SEPTEMBER 2010
- OTHER/COMBINED VACCINE TECHNOLOGY
- TABLE 100 PATENTS BY ASSIGNEE UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY,
2006 TO SEPTEMBER 2010
- FIGURE 53 PATENTS BY ASSIGNEE UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY,
2006 TO SEPTEMBER 2010
Chapter-12: CURRENT SITUATION OF THE GLOBAL VACCINES MARKET
- FACTORS AFFECTING THE SALES OF VACCINES
- COMPETITION
- COST
- TRENDS
- IMMUNIZATION FUNDING
- GLOBAL IMMUNIZATION VISION AND STRATEGY (GIVS)
- TABLE 101 AIMS OF GIVS
- TABLE 102 GOALS OF GIVS
- TABLE 103 STRATEGIES OF GIVS
- CURRENT SITUATION
- TABLE 104 GLOBAL FUNDING GAP BY REGION FOR IMMUNIZATION WORK, 2010-2011 ($
MILLIONS)
- VACCINE PREVENTABLE DISEASES UPDATE
- CURRENT VACCINE PRIORITIZATION
- TABLE 105 VACCINE PRIORITIZATION, 2009-2010
- CURRENT AND FUTURE (PROPOSED) VACCINE MILESTONES
- TABLE 106 VACCINE MILESTONES 2009-2012
- INFLUENZA VIRUS VACCINES UPDATE FOR THE 2010 THROUGH 2011 SEASON
- TABLE 107 INFLUENZA VACCINES FOR THE 2010 - 2011 SEASON
Chapter-13: COMPANY PROFILES
- BAYER ANIMAL HEALTH
- BUL BIO - NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD. (BB
- NCIPD LTD.)
- BHARAT BIOTECH
- BIO FARMA
- BIOLOGICAL E. LIMITED
- BIO - MANGUINHOS
- BIOPROPERTIES
- BOEHRINGER INGELHEIM VETMEDICA, INC.
- CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY
- CEVA SANTE ANIMALE
- COLORADO SERUM COMPANY
- CRUCELL
- CSL LTD.
- ELI LILLY & CO.
- EMERGENT BIOSOLUTIONS
- FATRO
- GLAXOSMITHKLINE
- GREEN CROSS
- HAFFKINE BIO - PHARMACEUTICAL CORPORATION LTD.
- INDOVAX
- INSTITUT PASTEUR DE DAKAR
- INTERCELL
- JAPAN BCG LABORATORY
- KING PHARMACEUTICALS INC.
- LOHMANN INTERNATIONAL
- MEDIMMUNE
- MERCK & CO., INC.
- NIPPON BIOLOGICALS, INC.
- NOVARTIS AG
- PANACEA BIOTEC
- PFIZER INC.
- ROMVAC
- SANOFI - AVENTIS (SANOFI PASTEUR)
- SERUM INSTITUTE OF INDIA LTD.
- STATENS SERUM INSTITUT
- THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY
- VENTRI BIOLOGICALS
- ZYDUS CADILA
Chapter-14: APPENDIX
- ABBREVIATIONS
- ABBREVIATIONS (CONTINUED)
|
